Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- Written by PR Newswire
 |
- XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan
- Antengene plans to submit for national health insurance reimbursement in Taiwan for XPOVIO® in Q4 2022
SHANGHAI and HONG KONG, Oct. 21, 2022 /PRNewswire/ -- Antengene...
